AU2009339802B2 - RBM3 as a marker for malignant melanoma prognosis - Google Patents

RBM3 as a marker for malignant melanoma prognosis Download PDF

Info

Publication number
AU2009339802B2
AU2009339802B2 AU2009339802A AU2009339802A AU2009339802B2 AU 2009339802 B2 AU2009339802 B2 AU 2009339802B2 AU 2009339802 A AU2009339802 A AU 2009339802A AU 2009339802 A AU2009339802 A AU 2009339802A AU 2009339802 B2 AU2009339802 B2 AU 2009339802B2
Authority
AU
Australia
Prior art keywords
sample
rbm3
subject
malignant melanoma
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009339802A
Other languages
English (en)
Other versions
AU2009339802A1 (en
Inventor
Karin Jirstrom
Fredrik Ponten
Mathias Uhlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Antibodies AB
Original Assignee
Atlas Antibodies AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/SE2009/000091 external-priority patent/WO2009102261A1/en
Priority claimed from EP09158084A external-priority patent/EP2241889A1/en
Priority claimed from EP09167847A external-priority patent/EP2293070A1/en
Application filed by Atlas Antibodies AB filed Critical Atlas Antibodies AB
Publication of AU2009339802A1 publication Critical patent/AU2009339802A1/en
Application granted granted Critical
Publication of AU2009339802B2 publication Critical patent/AU2009339802B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2009339802A 2009-02-16 2009-12-17 RBM3 as a marker for malignant melanoma prognosis Ceased AU2009339802B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
AUPCT/SE2009/000091 2009-02-16
PCT/SE2009/000091 WO2009102261A1 (en) 2008-02-15 2009-02-16 Rbm3 as a marker for breast cancer prognosis
US16996309P 2009-04-16 2009-04-16
EP09158084.5 2009-04-16
EP09158084A EP2241889A1 (en) 2009-04-16 2009-04-16 RBM3 protein in colorectal cancer prognostics
US61/169,963 2009-04-16
US23376909P 2009-08-13 2009-08-13
US61/233,769 2009-08-13
EP09167847.4 2009-08-13
EP09167847A EP2293070A1 (en) 2009-08-13 2009-08-13 Means and methods for ovarian cancer prognosis
PCT/EP2009/067419 WO2010091763A1 (en) 2009-02-16 2009-12-17 Rbm3 as a marker for malignant melanoma prognosis

Publications (2)

Publication Number Publication Date
AU2009339802A1 AU2009339802A1 (en) 2011-07-28
AU2009339802B2 true AU2009339802B2 (en) 2014-07-24

Family

ID=41718882

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2009339802A Ceased AU2009339802B2 (en) 2009-02-16 2009-12-17 RBM3 as a marker for malignant melanoma prognosis
AU2010212769A Ceased AU2010212769C1 (en) 2009-02-16 2010-02-16 RBM3 protein in testicular cancer diagnostics and prognostics
AU2010212764A Ceased AU2010212764B2 (en) 2009-02-16 2010-02-16 RBM3 protein in colorectal cancer prognostics
AU2010212772A Ceased AU2010212772B2 (en) 2009-02-16 2010-02-16 Prediction of response to platinum-based therapy

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2010212769A Ceased AU2010212769C1 (en) 2009-02-16 2010-02-16 RBM3 protein in testicular cancer diagnostics and prognostics
AU2010212764A Ceased AU2010212764B2 (en) 2009-02-16 2010-02-16 RBM3 protein in colorectal cancer prognostics
AU2010212772A Ceased AU2010212772B2 (en) 2009-02-16 2010-02-16 Prediction of response to platinum-based therapy

Country Status (8)

Country Link
US (3) US8632984B2 (OSRAM)
EP (4) EP2396657B1 (OSRAM)
JP (3) JP5767116B2 (OSRAM)
CN (1) CN102334032B (OSRAM)
AU (4) AU2009339802B2 (OSRAM)
CA (3) CA2749392A1 (OSRAM)
DK (2) DK2396659T3 (OSRAM)
WO (5) WO2010091763A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
AU2011316844A1 (en) * 2010-10-22 2013-06-06 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
US20120288480A1 (en) * 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
EP2573566A1 (en) 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
CN102590185B (zh) * 2012-01-11 2013-12-25 东南大学 以适体为识别单元的胶体晶体凝胶非标记可视化检测方法
WO2016004387A1 (en) * 2014-07-02 2016-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene expression signature for cancer prognosis
EP3023791A1 (en) 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
CN106611094B (zh) * 2015-10-15 2021-08-06 北京寻因生物科技有限公司 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统
CN113373151B (zh) * 2021-06-30 2022-05-03 华中科技大学同济医学院附属协和医院 环状RNAhsa_circ_0008399的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2006071896A2 (en) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Epitope-based sars vaccine
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008051260A1 (en) 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP1862803A1 (en) * 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP2090890A1 (en) * 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US7902166B2 (en) 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) * 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANNO, S., et al., AM J PATHOL, 2000, vol. 156, pages 1685-1692 *
DRESIOS J., et al., PROC NAT ACAD SCI USA, 2005, vol. 102, , pages 1865-1870 *
NILSSON P., et al., PROTEOMICS, 2005, vol. 5, PAGE 4327-4337 *
SUREBAN, S. M., et al., ONCOGENE, 2008, vol. 27, pages 4544-4556 *

Also Published As

Publication number Publication date
JP2012518163A (ja) 2012-08-09
US8632984B2 (en) 2014-01-21
US20120034317A1 (en) 2012-02-09
CA2749350A1 (en) 2010-08-19
JP2012518162A (ja) 2012-08-09
AU2009339802A1 (en) 2011-07-28
AU2010212769A1 (en) 2011-07-28
WO2010092190A2 (en) 2010-08-19
CA2749349A1 (en) 2010-08-19
EP2396659B1 (en) 2012-11-21
WO2010091763A1 (en) 2010-08-19
EP2396659A1 (en) 2011-12-21
DK2396660T3 (da) 2013-10-28
JP5767116B2 (ja) 2015-08-19
AU2010212769B2 (en) 2014-07-17
CA2749392A1 (en) 2010-08-19
CN102334032A (zh) 2012-01-25
EP2396657A1 (en) 2011-12-21
EP2396346A1 (en) 2011-12-21
EP2396346B1 (en) 2013-04-03
AU2010212772B2 (en) 2014-07-17
EP2396660B1 (en) 2013-07-24
CN102334032B (zh) 2015-01-28
EP2396657B1 (en) 2013-11-13
AU2010212769C1 (en) 2014-10-09
JP5669757B2 (ja) 2015-02-18
WO2010092182A1 (en) 2010-08-19
HK1166371A1 (en) 2012-10-26
DK2396659T3 (da) 2013-03-04
EP2396660A2 (en) 2011-12-21
WO2010092190A3 (en) 2010-11-04
AU2010212764A1 (en) 2011-07-28
JP5611986B2 (ja) 2014-10-22
AU2010212764B2 (en) 2014-07-17
JP2012518164A (ja) 2012-08-09
WO2010092187A1 (en) 2010-08-19
US8747910B2 (en) 2014-06-10
WO2010092184A1 (en) 2010-08-19
AU2010212772A1 (en) 2011-07-28
US20120058202A1 (en) 2012-03-08
US20120269764A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
AU2010311540B9 (en) PODXL protein in colorectal cancer
US8632984B2 (en) RBM3 as a marker for malignant melanoma prognosis
US9416176B2 (en) RBM3 protein in colorectal cancer prognostics
US9354232B2 (en) PODXL in bladder cancer
EP2293070A1 (en) Means and methods for ovarian cancer prognosis
EP2241889A1 (en) RBM3 protein in colorectal cancer prognostics

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired